论文部分内容阅读
目的应用联合微创介入方法治疗中晚期肝癌并探讨其疗效。方法我院自1998年4月至2008年11月期间采用联合介入治疗的方法 ,即行经皮股动脉插管肝动脉化疗栓塞术,同期行B超引导下经皮穿刺瘤内乙醇注射(PEI)治疗中晚期肝癌175例。结果左肝动脉行肝动脉化疗栓塞7例,右肝动脉行125例,单行化疗而未栓塞43例;175例均行B超引导下PEI。随访6～28个月,平均19.3个月,死亡15例,其中8例死于肝功能衰竭,7例死于上消化道大出血伴肝癌广泛转移。29例存活6～12个月;146例存活13～28个月,其中27例存活已超过26个月。结论对于不能切除的中晚期肝癌采用联合介入治疗,因其具有操作简单、疗效可靠、经济、安全等优点,值得临床推广应用。
Objective To evaluate the efficacy of combined minimally invasive interventional therapy for advanced hepatocellular carcinoma. Methods In our hospital from April 1998 to November 2008 using a combination of interventional approach, that is, percutaneous transhepatic artery embolization of hepatic artery chemoembolization, the same period underwent B-guided percutaneous nephrotic ethanol injection (PEI) Treatment of 175 cases of advanced liver cancer. Results In the left hepatic artery, hepatic arterial chemoembolization was performed in 7 cases, in the right hepatic artery in 125 cases, in the chemotherapeutic group without embolization in 43 cases, and in 175 cases undergoing B-guided PEI. All cases were followed up for 6 ~ 28 months with an average of 19.3 months. There were 15 deaths, of which 8 died of liver failure and 7 died of upper gastrointestinal bleeding with extensive metastasis of liver cancer. 29 patients survived 6 to 12 months; 146 patients survived 13 to 28 months, of which 27 patients survived more than 26 months. Conclusion For the unresectable advanced hepatocellular carcinoma, the combined interventional therapy has the merits of simple operation, reliable curative effect, economy and safety, so it is worthy of clinical application.